Search company, investor...

Oriel Therapeutics

Founded Year



Acquired | Acquired

Total Raised


About Oriel Therapeutics

Oriel Therapeutics is a respiratory drug delivery company developing dry powder delivery systems for the treatment of asthma and COPD. On April 19, 2010, Oriel Therapeutics was acquired by Sandox. The terms of the transaction were not disclosed.

Headquarters Location

630 Davis Drive Suite 120

Durham, North Carolina, 27713,

United States


Missing: Oriel Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Oriel Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Oriel Therapeutics Patents

Oriel Therapeutics has filed 33 patents.

patents chart

Application Date

Grant Date


Related Topics




Dosage forms, Drug delivery devices, Routes of administration, Medical equipment, Medical treatments


Application Date


Grant Date



Related Topics

Dosage forms, Drug delivery devices, Routes of administration, Medical equipment, Medical treatments



Oriel Therapeutics Frequently Asked Questions (FAQ)

  • When was Oriel Therapeutics founded?

    Oriel Therapeutics was founded in 2001.

  • Where is Oriel Therapeutics's headquarters?

    Oriel Therapeutics's headquarters is located at 630 Davis Drive, Durham.

  • What is Oriel Therapeutics's latest funding round?

    Oriel Therapeutics's latest funding round is Acquired.

  • How much did Oriel Therapeutics raise?

    Oriel Therapeutics raised a total of $11.5M.

  • Who are the investors of Oriel Therapeutics?

    Investors of Oriel Therapeutics include Sandoz, New Leaf Venture Partners, University of North Carolina at Chapel Hill, CHL Medical Partners, PPD and 4 more.

  • Who are Oriel Therapeutics's competitors?

    Competitors of Oriel Therapeutics include Erydel, Savara, MediQuest Therapeutics, Taiwan Liposome Company, Pacira Biosciences and 13 more.

Compare Oriel Therapeutics to Competitors

EZRA Innovations

EZRA Innovations currently holds exclusive worldwide rights in a controlled-release drug delivery system. Drug Surfactant Complex (DSC) Deoxycholate is used in combination with active pharmaceutical ingredients (API), DSC possesses the ability to change the chemical moiety of existing drugs and better extend release rates.

Biomed Vision Technologies L.C.

BioMed Vision Technologies LC (BMVT) has a particular interest in the development of veterinary medical equipment for diagnosing ocular diseases and systems for drug delivery such as programmable pumps for ocular medications delivery in horses and dogs. BMVT is also in the process of developing software applications for electronic management of medical records.

Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.


utilized "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds.�MACUGEN, approved for wet age-related macular degeneration, was discovered using this technology. Upon NeXagen's merger with Vestar, Inc., the company also marketed and developed liposomal drug delivery products.

Core Tech Solutions

Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.


EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.